Short interviews about Big Ideas


Interview with Rob Wills

Janssen Pharmaceuticals


As one of the most well-respected business development executives in the industry, Rob Wills of Janssen has seen it all. In this interview, Rob shares his views on the state of innovation in the industry and tangible advice for biotechs trying to secure a pharma partnership.

Interview conducted by Constantine Theodoropulos of Base Pair Group

Interview with Sander Slootweg

Forbion Capital


Sander Slootweg of Forbion Capital discusses the different investment climate in Europe and the US, and how Forbion is helping portfolio companies navigate the changeable investment terrain.

Interview conducted by Constantine Theodoropulos of Base Pair Group

Interview with Ed Mathers

Partner, NEA


Is the industry suffering a crisis of innovation, or a crisis of investment? Ed Mathers of NEA shares his views on how to keep the engines of biotech running.

Interview conducted by Constantine Theodoropulos of Base Pair Group

   

Interview with Shaun Grady

VP, Strategic Partnering and Business Development, AstraZeneca


Shaun Grady of AstraZeneca discusses the high cadence of partnering deals in 2012, and the firm′s strategy to become the partner of choice in the industry.

Interview conducted by Constantine Theodoropulos of Base Pair Group

   

Interview with Kevin Krenitsky

COO, Foundation Medicine


Foundation Medicine is blazing new trails in personalized medicine for cancer patients. In this interview, Kevin discusses Foundation Medicine’s strategy for achieving true personalized medicine in the oncology market.

Interview conducted by Constantine Theodoropulos of Base Pair Group

   

Interview with Jason Rhodes

CBO and EVP, Epizyme


Epizyme is aiming to create personalized therapeutics for patients with genetically-defined cancers using a branch of epigenetics called histone methyltransferases (HMTs).

Interview conducted by Toby Zaleski of Base Pair Group

   

Interview with Garry Neil

CEO, TransCelerate


Garry Neil explains the impetus behind and goals of TransCelerate BioPharma, a new nonprofit organization focused on accelerating the development of new medicines.

Interview conducted by Constantine Theodoropulos of Base Pair Group

   

Interview with David de Graaf

President and CEO, Selventa


With it increasingly clear that current molecular diagnostic test (MoDx) offerings are limited in their ability to capture the majority of disease-relevant biomarkers, the need for new solutions is necessary. Novel tests that are able to harness big data present the opportunity to replace the standard of care with data-driven treatment algorithms based on an individual’s disease characteristics. David de Graaf discusses the advent of “systems diagnostic” tests that will finally enable physicians to determine which treatments are going to work for which patients ahead of time.

Interview conducted by Constantine Theodoropulos of Base Pair Group

   

Interview with John Brooks

CEO, Joslin Diabetes Center


With 8.3 percent of the US population and >300M people worldwide projected to have diabetes, understanding, treating and slowing this pandemic is paramount. John Brooks explains how the Joslin Diabetes Center is on the forefront in tackling this disease, and is positioned as the hub of innovation and research partnerships in diabetes.

Interview conducted by Constantine Theodoropulos of Base Pair Group

   

Interview with Stephen Evans-Freke

Co-Founder and Managing General Partner, Celtic Therapeutics


Stephen Evans-Freke has an enviable career by any measure. Successful entrepreneur, CEO, and now investor at the hedge fund Celtic Therapeutics, Evans-Freke shares his views on investment strategy in the current financial climate.

Interview conducted by Constantine Theodoropulos of Base Pair Group

   

Interview with Richard Soll

Senior VP, Integrated Services and Head, Corporate Alliances, WuXi AppTec


Since its founding in 2000, WuXi AppTec has grown to become one the industry's leading CROs. Richard Soll discusses WuXi's approach to working with both big pharma and smaller biotech, and how the company is increasingly positioned as the gateway company into the high growth China life science market.

Interview conducted by Constantine Theodoropulos of Base Pair Group

   

Interview with Christian Rohlff

CEO, Oxford BioTherapeutics


Oncology is where new approaches to targeted therapy appear first. Christian Rohlff, Founder and CEO of Oxford BioTherapeutics, discusses his company's unique targeted antibody-based platform for developing new drugs and companion diagnostics, and partnering-driven growth strategy.

Interview conducted by Constantine Theodoropulos of Base Pair Group